Dronedarone reduces arterial thrombus formation

Basic Research in Cardiology

Volumn 107, Issue 6, 2012, Pages

  Breitenstein, Alexander ^a,b   Sluka, Susanna H M ^b   Akhmedov, Alexander ^b   Stivala, Simona ^b   Steffel, Jan ^a,b   Camici, Giovanni G ^a,b   Riem, Huy H ^a   Beer, Hans Jurg ^c   Studt, Jan Dirk ^a   Duru, Firat ^a,b   Luscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Cantonal Hospital Baden   (Switzerland)

Author keywords

Animal model; Arterial thrombosis; Dronedarone; Platelets

Indexed keywords

COLLAGEN; DRONEDARONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; C57BL 6 MOUSE; CAROTID ARTERY THROMBOSIS; CHEMICAL INJURY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTEIN EXPRESSION; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84866665177     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0302-4     Document Type: Article

References (26)

1. Breitenstein A, Camici GG, Tanner FC (2009) Tissue factor: beyond coagulation in the cardiovascular system. Clin Sci 118:159-172. doi:10.1042/CS20080622
2. Breitenstein A, Tanner FC, Luscher TF (2010) Tissue factor and cardiovascular disease: quo vadis? Circ J 74:3-12. doi:10.1253/circj. CJ-09-0818
3. Bukowska A, Hammwohner M, Sixdorf A, Schild L, Wiswedel I, Rohl FW, Wolke C, Lendeckel U, Aderkast C, Bochmann S, Chilukoti RK, Mostertz J, Bramlage P, Goette A (2012) Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol 166:964-980. doi:10.1111/j.1476-5381.2011.01784.x
4. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC (2006) Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 114:1512-1521. doi:10.1161/CIRCULATIONAHA.106.638460 (Pubitemid 44527007)
5. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365:2268-2276. doi:10.1056/NEJMoa1109867
6. Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 375:1212-1223. doi: 10.1016/S0140-6736 (10) 60096-7
7. Dorian P (2010) Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 15:15S-18S. doi:10.1177/1074248410367792
8. Engelhorn T, Schwarz MA, Heusch G, Doerfler A, Schulz R (2011) Reduction of cerebral infarct size by dronedarone. Cardiovasc Drugs Ther 25:523-529. doi:10.1007/s10557-011-6336-2
9. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP (1998) Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97:1002-1008. doi:10.1161/01. CIR.97.10.1002 (Pubitemid 28125473)
10. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370-2375. doi:10.10 01/jama.285.18.2370 (Pubitemid 32424106)
11. Guiraudou P, Pucheu SC, Gayraud R, Gautier P, Roccon A, Herbert JM, Nisato D (2004) Involvement of nitric oxide in amiodarone-and dronedarone-induced coronary vasodilation in guinea pig heart. Eur J Pharmacol 496:119-127. doi:10.101 6/j.ejphar.2004.05.046 (Pubitemid 39024324)
12. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949-953. doi:10.1093/eurheartj/ehi825
13. Heusch G, Schulz R (2012) Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain. Cardiovasc Drugs Ther 26:257-263. doi:10.1007/s10557-012-6379-z
14. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668-678. doi:10.1056/NEJMoa0803778
15. Kawasaki T, Dewerchin M, Lijnen HR, Vermylen J, Hoylaerts MF (2000) Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96:153-160 (Pubitemid 30456465)
16. Kimmelstiel C (2012) The effect of differing pharmacologic strategies on infarct size in primary PCI-more confirmatory data for bivalirudin. Catheter Cardiovasc Interv 79:1090-1091. doi: 10.1002/ccd.24455
17. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J, Dronedarone Study Group (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678-2687. doi:10.1056/NEJM oa0800456 (Pubitemid 351860860)
18. Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451:914-918. doi:10.1038/nature06797 (Pubitemid 351301746)
19. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH (2007) Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357:987-999. doi:10.1056/ NEJMoa054686 (Pubitemid 47367078)
20. Skyschally A, Heusch G (2011) Reduction of myocardial infarct size by dronedarone in pigs-a pleiotropic action? Cardiovasc Drugs Ther 25:197-201. doi:10.1007/s10557-011-6300-1
21. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H (1998) Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97:2213-2221. doi:10.1161/01. CIR.97.22.2213 (Pubitemid 28265382)
22. Steffel J, Luscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113:722-731. doi:10.1161/CIRCULA TIONAHA.105.567297
23. Thygesen K, Alpert JS, White HD (2007) Universal definition of myocardial infarction. J Am Coll Cardiol 50:2173-2195. doi: 10.1016/j.jacc.2007.09.011 (Pubitemid 350123680)
24. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH (2003) Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24:1481-1487. doi: 10.1016/S0195-668X (03) 00321-X (Pubitemid 37010577)
25. Varro A, Takacs J, Nemeth M, Hala O, Virag L, Iost N, Balati B, Agoston M, Vereckei A, Pastor G, Delbruyere M, Gautier P, Nisato D, Papp JG (2001) Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol 133:625-634. doi:10.1038/sj.bjp. 0704106 (Pubitemid 32642867)
26. Weber AA, Reimann S, Schror K (1999) Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 126:415-420. doi:10.1038/sj.bjp. 0702276 (Pubitemid 29057591)